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Abstract: A chemotherapy induced phlebitis severity (CIPS) scale was developed in patients
receiving anthracycline chemotherapy for breast cancer. A five-point severity scoring scale for
chemotherapy-induced phlebitis was tested for inter-rater reliability. Ease of use was observed
through timing assessments and a review of the completeness of documentation. A comparison of
CIPS scale grade with participant reported severity scores was made. The final version was tested
for inter-rater reliability, with 122 patient assessments. There was an 89.3% (109 of 122) agreement
between the assessors (κ = 0.82, SE ± 0.042, 95% CI 0.74–0.90). Mean time to complete the scale
was 1 min 36 s and documentation was fully completed for 98% of assessments. Patient reported
severity closely matched the CIPS grade (κ = 0.54, SE ± 0.045, 95% CI 0.46–0.63). This new scale
provides a list of symptoms associated with chemotherapy phlebitis, which can be scored quickly
and accurately. It provides a reliable method for assessing chemotherapy-induced phlebitis, enabling
a better understanding of its impact on patients’ quality of life, and to inform the appropriate
choice of peripheral or central intravenous administration. Multicentre testing of the CIPS scale
is recommended.
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1. Introduction
Despite the use of new targeted therapies and improved cancer detection, chemotherapy treatment
continues to play a major role in cancer treatment [1]. It is well documented that the administration of
chemotherapy can result in significant toxicities and complications. One recognised consequence of
peripheral administration of some intravenous chemotherapy is venous irritation leading to phlebitis
and thrombophlebitis resulting from the chemical effects of the drug on the vein wall [2,3]. Chemical
phlebitis causes symptoms such as pain, swelling, redness and, at worst, hardening and sclerosis of the
vein resulting in a palpable venous cord and thrombosis of the upper extremity veins [4,5]. It has been
recommended that a central venous catheter (CVC) should be used for the administration of drugs
which are known to cause significant venous irritation and phlebitis [6]. However, the decision to place
a CVC needs to be carefully assessed, taking into consideration the risk of infection and thrombosis
associated with central line placement [7], compared with the severity and impact of phlebitis.
At their most severe, phlebitis symptoms can last for months following the completion of
chemotherapy, which can have a considerable impact on patients’ quality of life and their ability to
J. Clin. Med. 2020, 9, 701; doi:10.3390/jcm9030701 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 701 2 of 9
carry out normal daily activities [8]. However, for patients who only experience mild and transient
symptoms, these may be viewed as an inconvenience requiring no clinical intervention, which would
not justify the additional risks and costs of placement of a central venous catheter [9]. The reported rates
of chemotherapy-induced phlebitis vary considerably from 3% to 89%, with the exact incidence and
severity being difficult to assess due to the different methodology and assessment scales used [10,11].
When trying to identify a suitable scale to assess the severity of chemotherapy-induced phlebitis, it
became evident that, despite the existence of a variety of scoring and assessment tools, there is, as yet,
no existing phlebitis assessment scale which specifically and comprehensively measures the effect of
chemical phlebitis as a result of peripheral chemotherapy infusions [12].
Commonly used phlebitis assessment scales, such as the visual infusion phlebitis (VIP) scale [13],
the phlebitis scale [14], and the Baxter scale [15], are designed to assess symptoms of phlebitis from an
indwelling peripheral cannula to identify when it should be replaced, and not to assess the delayed
effects of chemical phlebitis following chemotherapy. Rittenberg et al. (1995) developed the only
available chemotherapy specific tool used for grading the venous irritation associated with vinorelbine
chemotherapy [16]. However, this scale does not include some of the common symptoms of chemical
phlebitis, such as a palpable venous cord, or use a scale to clarify levels of pain which may increase the
risk of subjectivity in assessment. The National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE, version 4.03), which is widely used to grade chemotherapy toxicities,
simply grades phlebitis as grade 2 if present, without providing any criteria for severity of symptoms.
The validity and reliability of all available phlebitis assessment scales has been questioned by
Ray-Barruel et al. (2015) and Göransson et al. (2017), who both conclude that no phlebitis scale has
been thoroughly validated, and raise concerns about whether they are fit for purpose [17,18]. Marsh et
al. (2015) assessed inter-rater agreements between nurses using ten different phlebitis scales with 210
patients [12]. They established that inter-rater agreement across the phlebitis scales was generally poor,
the Rittenberg scale was identified as one of the best with >80% agreement, and they recommended
further development of this tool.
This study aims to develop a chemotherapy induced phlebitis severity (CIPS) scale, which provides
a comprehensive and reliable measure of the severity of chemotherapy-induced phlebitis, which can
be used to help assess the impact on patients and inform the choice of intravenous access.
2. Methods
The CIPS scale was developed by a team of three specialist nurses with expertise in breast cancer,
intravenous access and chemotherapy, all with over 20 years’ clinical experience in oncology and
qualified at Master’s level. An expert nurse is deemed to possess widespread clinical experience and
an extensive body of knowledge [19].
The CIPS scale was designed with five levels of symptom grades, in order of severity from zero to
four. The choice of grading levels was based on the grade descriptors used by the National Cancer
Institute Common Terminology Criteria for Adverse Events version 4 (NCI-CTCAE, 2009), which is
well known to clinical staff working in oncology [20]. Grade zero denotes no symptoms; grade one
mild, grade two moderate, grade three marked and grade four severe. In addition, the effect on arm
function, which is a key distinguishing feature of Rittenberg’s (1995) scale, was considered important
for the CIPS scale to ensure that the impact of chemotherapy-induced phlebitis on patients was taken
into consideration when grading the severity of symptoms [16]. The final wording chosen to describe
the effect on function in the CIPS scale was influenced by the NCI-CTCAE, which uses the effect of
symptoms on activities of daily living (ADL) as a key measure to indicate the severity and impact of
symptoms on patients [20].
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The scale includes the widely recognised symptoms of phlebitis redness, swelling and pain [17].
The CIPS scale also includes the addition of other symptoms, not consistently found in generic
phlebitis assessments tools, but frequently seen with chemotherapy-induced chemical phlebitis,
namely; tethering, palpable venous cord, vein discolouration and impaired arm function. To better
evaluate the pain experienced by patients, a Likert scale was used to determine the severity of the
discomfort from 0–10, with 10 being the most severe (Figure 1). A score of 1–3 was described as mild
pain, 4–7 as moderate and 8–10 as severe. This pain score was then utilised within the assessment scale
to assist in the determination of the severity of the overall symptoms.
Figure 1. Likert scale for pain assessment.
The CIPS scale was initially piloted in 2015 in a prospective audit of 51 patients receiving 75 cycles
of chemotherapy to identify the severity of the symptoms of chemical phlebitis. During this audit,
the scale was reviewed and amended from version 1–3 to improve the definitions of the symptoms of
chemical phlebitis within each grade. The scale was then tested for inter-rater reliability by the three
expert nurses for a further 85 patient assessments. Inter-rater reliability is used to establish whether a
scale or measure produces consistent results when used by different assessors and is recommended as
one of the key methods to test the reliability of phlebitis assessment scales [12,17].
During this testing, a series of minor amendments were made to the wording used, clarifying
the grade descriptors to improve consistency in interpretation of symptoms. For example, replacing
‘impairment of arm function or movement’ with ‘effect on activities of daily living (ADL)’, to be
consistent with the NCI CTCAE terminology, and the inclusion of ‘inability to use arm for further
chemotherapy’ in grade 4, to reflect Rittenberg’s grading scale [20]. The final version of the phlebitis
scale (Figure 2) was used for testing for inter-rater reliability in this study. Ethical approval to use
the CIPS scale was included as part of a study on anthracycline induced phlebitis (REC reference:
16/WA/0074) [9].
Six practitioners were recruited to take part in the inter-rater reliability assessments of the
final version of the scale. All were nurses practising in breast cancer, chemotherapy or intravenous
access. They received guidance on the use of the CIPS scale from the initial group of expert nurses
who developed the scale. Following a verbal agreement from the patient, two assessors used the
measurement scale to grade phlebitis in separate assessments a few minutes apart.
In addition to inter-rater reliability assessments, feasibility of use in practice was tested by timing
the assessment using the scale and reviewing whether all documentation on the assessment form was
complete. The CIPS scale grade recorded by clinical staff was then compared with participant reported
severity of symptoms.
A statistical analysis was performed using the Statistical Package for Social Science software (V25,
SPSS, IBM, New York, NY, USA).
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Figure 2. The chemotherapy-induced phlebitis severity scale.
3. Results
A total of 122 assessments were performed during the inter-rater reliability testing process from
November 2016–March 2018. A convenience sample of patients, attending for routine assessment
between anthracycline chemotherapy treatments, were used for the testing.
The inter-rater agreement for all assessors, with grade given on review, was high at 86.9% (106
out of 122), Cohen’s kappa (κ), 0.82 (SE 0.04, 95% CI’s 0.74–0.90) (Table 1).
Table 1. Agreement between assessors by symptom grade.
Grade Assessments n (%) Agreement n (%)
Grade 0 44 (36) 41 (93)
Grade 1 29 (24) 26 (90)
Grade 2 33 (27) 26 (79)
Grade 3 13 (11) 13 (100)
Grade 4 3 (2) 3 (100)
The time taken to complete the assessment for a nurse experienced with using the scale was
measured for 25 assessments (Table 2). The mean time to complete was 1 min 36 s (range 42 s–2 min
51 s). Out of 122 assessments, assessor 1 fully completed 98% (120 of 122) of the assessment forms and
assessor 2 fully completed 97% (118 of 122) of the assessment forms.
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Table 2. Time taken for assessor to complete chemotherapy induced phlebitis severity (CIPS) scale (V8).
Grade Number of Assessments Mean Time Taken
0 9 1 min 8 s
1 8 1 min 42 s
2 7 2 min 10 s
3 1 1 min 14 s
4 0 NA
All grades 25 1 min 36 s
After development and testing for inter-rater reliability the final version of CIPS was used for
a study of anthracycline induced phlebitis [9]. Included in this study was a questionnaire, enabling
patients to self- report and score any phlebitis symptoms, which was used in parallel with the staff
assessment of symptoms using the CIPS scale. The patient reported severity scores compared to the
staff CIPS scale grading (Table 3) demonstrated a good level of agreement (κ = 0.54, SE ± 0.045, 95%
CI 0.46–0.63). As the patient reported severity score increased, the severity of the CIPS scale grade
increased by 77% (57 of 66), and participants reporting no symptoms were graded as CIPS scale 0 or 1,
and all 7 patients who reported severe symptoms were graded by staff as CIPS grade 3 or 4.
Table 3. Patient reported symptom severity compared with CIPS scale.
CIPS Scale Grade
Patient Reported Symptom Severity
None n = 66 Mild n = 101 Moderate n = 55 Severe n = 7
Grade 0 38 (58%) 3 (3%) 0 0
Grade 1 19 (29%) 59 (58%) 3 (5%) 0
Grade 2 5 (8%) 33 (33%) 17 (31%) 0
Grade 3 4 (6%) 5 (5%) 30 (55%) 5 (71%)
Grade 4 0 1 (1%) 5 (9%) 2 (29%)
The comparison of patient reported severity of symptoms with staff assessment of grade using the CIPS scale is
illustrated with red indicating the highest proportion of CIPS grade recorded for each level of participant reported
symptoms, amber illustrating where the proportion was <10% and green where it was zero.
4. Discussion
The choice of the intravenous access route to administer chemotherapy should be made after an
informed discussion with the patient about the risks and benefits of both peripheral and central venous
administration. The potential risks of infection and thrombosis with central venous catheters are well
documented [7,21], but it is currently difficult to provide patients with an accurate understanding of the
potential severity and impact of chemotherapy-related phlebitis, which may influence venous access
choices. Despite the number of assessment scales available to monitor phlebitis, there is no suitable
scale that can be used specifically to assess and provide accurate information about the frequency
and severity of chemotherapy-related chemical phlebitis. A standardised tool available for assessing
chemotherapy-induced phlebitis as opposed to infective phlebitis would allow the routine reporting of
this condition and provide prevalence rates to be collected at a local and national level; something
which is not currently possible.
From a cancer perspective, the National Cancer Institute’s (NCI) Common Terminology
Criteria for Adverse Events (CTCAE), which is extensively used to standardise the assessment
of chemotherapy-related toxicities, fails to adequately address the issues of post treatment phlebitis [20].
This was also recognised by Rittenberg et al. (1995) when studying venous irritation resulting from
peripheral administration of the chemotherapy drug vinorelbine [16]. As the NCI CTCAE phlebitis
grading did not provide any opportunity to grade the severity of symptoms, Rittenberg et al. developed
the Venous Irritation Record (VIR). The VIR devised specifically for chemotherapy-related phlebitis
described common symptoms of phlebitis such as redness, swelling and pain but importantly also
included impairment of arm function to enable a better assessment of the impact on the patient.
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However, the assessment of pain in the VIR is based on the level of analgesia required, which is not a
widely recognised method of assessing pain, and additional symptoms such as venous cord formation,
tethering and streak formation that can determine the presence and severity of chemical phlebitis were
not included. The CIPS scale has incorporated these symptoms along with a Likert scale to measure
the level of discomfort and pain experienced (Figure 1). This allows a more comprehensive approach
to the assessment of chemotherapy-induced phlebitis
When introducing any new assessment scale into clinical practice, it is important to consider
how feasible it is for busy clinical staff to use. If an assessment scale is not quick and easy to use,
staff compliance with undertaking accurate assessments will be poor, and this will adversely affect its
reliability in practice. The significance of assessing for feasibility was acknowledged by Ray-Barruel et
al. (2014) in their systematic review of phlebitis assessment measures, recommending that factors such
as the length of time to complete, as the ease of use and clarity of instructions were key indicators of
excellence in clinical measurement scales [17]. The feasibility of the CIPS scale was primarily evaluated
by recording the time from start to completion of assessment. The average time was 1 min 30 s, with
the shorter assessment times being predominately associated with the higher or lower grades. Grade
two, on average, took longer (2 min 10 s), and this may be explained by the additional time taken to
evaluate the significance of symptoms, which clearly did not meet the obvious criteria for the lowest or
highest grades. Interestingly, Grade 2 also had the greatest inconsistencies of assessment, possibly
because it was the midpoint of the scale, and symptoms may be a combination of lower and higher
individually graded symptoms. Feasibility and ease of use in practice were also demonstrated by the
high number of assessment forms with documentation fully completed, which was between 97%–98%.
Reliability of the CIPS scale was tested using inter-rater agreement, which was strong with the
items tested, demonstrating a high degree of agreement between assessors (Table 1). Overall, there was
89.3% (109 of 122) agreement between the assessors (κ = 0.82, SE ± 0.042, 95% CI 0.74–0.90). Although
the number of assessments recording grade 3 or 4 was small (16 of 122), there was 100% agreement
between assessors, giving some confidence that the scale enables staff to consistently identify the most
severe symptoms. There were some inconsistencies in the assessment of a small number of patients,
and as with most assessment tools, there will inevitably be some degree of inconsistency, as it relies on
individual clinical judgment that can lead to subjectivity. Steps were taken to attempt to eliminate
this, such as the use of a Likert scale to measure pain, and the inclusion of definitions of ‘tethering’
and ‘palpable venous cord’ to guide the users’ assessment. In addition, the immediacy of the two
assessments reduces the potential for conflicting findings, as a result of a time-lapse.
There was a variation between the levels of pain recorded between the first and second assessor
in four cases. An increase in the level of pain on the second assessment may be a result of the patient
becoming more aware of the symptoms, or that the physical palpation by the first assessor increased
the levels of pain, and the possibility of this was also identified by Marsh et al. (2015) [12] However,
the reduction in the level of pain from assessor 1 to assessor 2 was unexpected, but could be explained
by the indecisiveness of the patient being assessed, as the level of pain bordered between points on the
Likert pain score. The need of training to use the CIPS scale was highlighted by the small number of
occasions, when one of the assessors failed to recognise tethering or the presence of a palpable venous
cord. The failure to identify painless tethering led us to recognise the importance of examining the arm
when fully extended, to facilitate the identification of tethering.
A key priority during the development of the CIPS scale was to include measurement of the
impact of chemical phlebitis on the patient. The effects on activities of daily living which reflect quality
of life are a key feature of the NCI’s model of toxicity assessment, which is used extensively in cancer
care. However very few of the current phlebitis measuring tools include this issue, with the exception
of the tool developed by Rittenberg et al. (1995), who included a question concerning arm function.
The CIPS scale extends this to measuring whether the limitations to daily activities are moderate or
significant, along with the level of pain experienced, which can help demonstrate the negative impact
chemical phlebitis has on quality of life and the ability to perform every day functions [16]. It also relies
J. Clin. Med. 2020, 9, 701 7 of 9
on the patient to report the impact on activities of daily living (ADL) with patient reported measure
being increasingly recognised as essential to evaluation of symptoms experienced [22].
The comparison of patient reported severity of symptoms with staff assessment of grade using the
CIPS scale (Table 3) demonstrated a good level of agreement (κ = 0.54, SE ± 0.045, 95% CI 0.46–0.63).
A small number of patients who reported no symptoms were graded by staff as having grade 2 or 3
symptoms—this appears to be related to patients who either underreported symptoms; for example,
not identifying discomfort as pain, or failing to identify hardness of the vein (palpable venous cord).
However, all patients reporting severe symptoms were given a CIPS grade of either 3 or 4, and 95% (52
of 55) of those reporting moderate symptoms were given CIPS grades of 2 or above. This can be seen
as providing a degree of face validity, as defined by Mokkink et al. (2012), in the Consensus based
Standards for the selection of health Measurement Instruments manual (COSMIN), by confirming the
ability of the scale to closely reflect the reality of the patients’ experience of chemotherapy-induced
phlebitis [23].
Limitations
Primarily only patients with breast cancer patients receiving anthracycline chemotherapy were
chosen to test the CIPS scale. Further evaluation with other chemotherapy regimens and other larger
patient groups would be recommended to assess its applicability to all chemotherapy agents and to
ensure it is a reliable effective measurement of chemotherapy-induced phlebitis. It is recognised that
the individuals involved in completing the CIPS scale were experienced chemotherapy or breast cancer
specialist practitioners with a thorough understanding of the signs of phlebitis and how to clinically
diagnose its symptoms. Further information concerning the feasibility of the CIPS scale could be
drawn from the evaluation of nurses with varied levels of experience completing the tool. To further
establish the validity of the CIPS scale, it should be tested in parallel with the Rittenberg scale [16],
the only other published chemotherapy specific phlebitis scale. It is recommended that the inter-rater
reliability, feasibility of use in practice, and ability to closely reflect patient reported symptoms of both
scales should be compared.
5. Conclusions
The aim of this study was to test a newly devised scale designed specifically to identify and measure
the severity of chemotherapy-related chemical phlebitis. The CIPS scale includes a comprehensive list
of recognised symptoms to grade the severity of phlebitis and the effects on the patients’ activities of
daily living. The CIPS scale is easy, quick, reliable and robust to use in the clinic and has been shown
to closely reflect the breast cancer patient’s experience of chemotherapy- induced phlebitis.
Although the focus throughout the testing was on phlebitis-related to anthracycline chemotherapy,
the CIPS scale could potentially be used in the assessment of all chemotherapy agents. It is
recommended that for a more complete patient assessment chemical phlebitis should be recorded
routinely along with other chemotherapy-related toxicities. This will enable a greater understanding of
the impact of chemotherapy treatment and provide data about phlebitis rates and severity to inform
evidence-based discussions with patients about the choice of central or peripheral venous access for
chemotherapy administration.
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